Clinical Trial

QLS1410 in Participants With Uncontrolled Hypertension

Enrolling by Invitation Phase 2
View on ClinicalTrials.gov →
Summary
The goal of this clinical trial is to measure the efficacy and safety of QLS1410 in participants with uncontrolled hypertension (uHTN) or treatment-resistant hypertension (rHTN). The main objective is to compare the difference in systolic blood pressure（SBP) change from baseline at Week 12 of treatment between participants receiving QLS1410 tablets and participants receiving placebo tablets.
Protocol Amendment History 1 change
critical Trial status changed: Not Yet Recruiting → Enrolling by Invitation 2026-05-23
Trial Details
NCT Number NCT07489612
Lead Sponsor Qilu Pharmaceutical Co., Ltd.
Conditions Hypertension (HTN)
Enrollment 260 participants
Start Date 2026-04
Primary Completion 2026-12 (estimated)
Study Completion 2027-03 (estimated)
Updated on ClinicalTrials.gov 2026-05-22